Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
ACADIA Pharmaceuticals Inc
(NASDAQ:ACAD)
21.42
Delayed Data
As of Dec 06
-0.87
/
-3.90%
Today’s Change
14.45
Today
|||
52-Week Range
33.99
+34.55%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest ACAD News
|
Press Releases
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
Dec 04 / Zacks.com - Paid Partner Content
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
Nov 28 / Zacks.com - Paid Partner Content
Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS
Dec 01 / Zacks.com - Paid Partner Content
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Nov 27 / Zacks.com - Paid Partner Content
bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How
Dec 01 / Zacks.com - Paid Partner Content
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
Nov 27 / Zacks.com - Paid Partner Content
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)
Nov 30 / Zacks.com - Paid Partner Content
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
Nov 24 / Zacks.com - Paid Partner Content
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
Nov 29 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
Nov 24 / Zacks.com - Paid Partner Content
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
Nov 28 / Zacks.com - Paid Partner Content